First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease features In the overall BOT+BAL treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results